CN102841153A - 一种丹灯通脑药物制剂的质量控制方法 - Google Patents
一种丹灯通脑药物制剂的质量控制方法 Download PDFInfo
- Publication number
- CN102841153A CN102841153A CN2012103402981A CN201210340298A CN102841153A CN 102841153 A CN102841153 A CN 102841153A CN 2012103402981 A CN2012103402981 A CN 2012103402981A CN 201210340298 A CN201210340298 A CN 201210340298A CN 102841153 A CN102841153 A CN 102841153A
- Authority
- CN
- China
- Prior art keywords
- scutellarin
- quality control
- dandengtongnao
- detection
- active component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- 238000003908 quality control method Methods 0.000 title claims abstract description 30
- 210000004556 brain Anatomy 0.000 title abstract description 5
- DJSISFGPUUYILV-UHFFFAOYSA-N UNPD161792 Natural products O1C(C(O)=O)C(O)C(O)C(O)C1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-UHFFFAOYSA-N 0.000 claims abstract description 80
- NPLTVGMLNDMOQE-UHFFFAOYSA-N carthamidin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=C(O)C(O)=C2C(=O)C1 NPLTVGMLNDMOQE-UHFFFAOYSA-N 0.000 claims abstract description 80
- DJSISFGPUUYILV-ZFORQUDYSA-N scutellarin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-ZFORQUDYSA-N 0.000 claims abstract description 80
- 229930190376 scutellarin Natural products 0.000 claims abstract description 80
- 238000001514 detection method Methods 0.000 claims abstract description 35
- 239000013558 reference substance Substances 0.000 claims abstract description 29
- 241001013934 Erigeron breviscapus Species 0.000 claims abstract description 15
- 239000007788 liquid Substances 0.000 claims abstract description 12
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 claims abstract description 11
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 claims abstract description 11
- 239000000463 material Substances 0.000 claims abstract description 10
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 9
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 9
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 7
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 7
- 238000004128 high performance liquid chromatography Methods 0.000 claims abstract description 6
- 238000012360 testing method Methods 0.000 claims description 69
- 239000000243 solution Substances 0.000 claims description 65
- 238000000034 method Methods 0.000 claims description 45
- OKKJLVBELUTLKV-UHFFFAOYSA-N methyl alcohol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 37
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 20
- 238000003556 assay Methods 0.000 claims description 15
- 238000009472 formulation Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 239000000945 filler Substances 0.000 claims description 10
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 10
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 10
- 239000000377 silicon dioxide Substances 0.000 claims description 10
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 235000005412 red sage Nutrition 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- LBDROUOCQSGOFI-UHFFFAOYSA-N methanol;phosphoric acid Chemical compound OC.OP(O)(O)=O LBDROUOCQSGOFI-UHFFFAOYSA-N 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 238000011003 system suitability test Methods 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- 239000011148 porous material Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 235000017276 Salvia Nutrition 0.000 abstract 1
- 238000010971 suitability test Methods 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 21
- 239000003814 drug Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 7
- 238000001914 filtration Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 241000132521 Erigeron Species 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000003727 cerebral blood flow Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 240000006859 Jasminum officinale Species 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000002946 Total quality control Methods 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- -1 sheet Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
样品号 | 样品量(g) | 测定含野黄芩苷量(mg/g) |
1 | 0.1448 | 未检出 |
2 | 0.1524 | 未检出 |
3 | 0.1552 | 未检出 |
4 | 0.1485 | 未检出 |
5 | 0.1542 | 未检出 |
6 | 0.1492 | 未检出 |
样品号 | 对照品浓度(mg/ml) | 野黄芩苷峰面积(mAu) |
1 | 0.0203 | 140.89 |
2 | 0.0324 | 240.49 |
3 | 0.0405 | 302.09 |
4 | 0.0809 | 599.81 |
5 | 0.1214 | 877.83 |
6 | 0.1619 | 1207.07 |
7 | 0.2023 | 1547.96 |
时间 | 5分钟 | 10分钟 | 15分钟 | 20分钟 |
样品1检测结果 | 2.6mg/粒 | 2.7mg/粒 | 2.7mg/粒 | 2.7mg/粒 |
样品2检测结果 | 2.8mg/粒 | 2.9mg/粒 | 2.9mg/粒 | 2.9mg/粒 |
样品编号 | 处理后检测 | 摆放24小时后检测 |
样品1 | 2.6mg/粒 | 2.6mg/粒 |
样品2 | 2.8mg/粒 | 2.8mg/粒 |
样品3 | 2.7mg/粒 | 2.7mg/粒 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210340298.1A CN102841153B (zh) | 2012-09-14 | 2012-09-14 | 一种丹灯通脑药物制剂的质量控制方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210340298.1A CN102841153B (zh) | 2012-09-14 | 2012-09-14 | 一种丹灯通脑药物制剂的质量控制方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102841153A true CN102841153A (zh) | 2012-12-26 |
CN102841153B CN102841153B (zh) | 2014-11-05 |
Family
ID=47368706
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210340298.1A Expired - Fee Related CN102841153B (zh) | 2012-09-14 | 2012-09-14 | 一种丹灯通脑药物制剂的质量控制方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102841153B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106596777A (zh) * | 2016-12-20 | 2017-04-26 | 神威药业集团有限公司 | 丹灯通脑制剂的质量控制方法 |
CN115957289A (zh) * | 2022-11-25 | 2023-04-14 | 国药集团同济堂(贵州)制药有限公司 | 一种柴葛畅原合剂制剂及其制备方法和检测方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1876022A (zh) * | 2005-05-09 | 2006-12-13 | 贵阳云岩西创药物科技开发有限公司 | 丹灯脑通药物制剂及其制备方法和质量控制方法 |
-
2012
- 2012-09-14 CN CN201210340298.1A patent/CN102841153B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1876022A (zh) * | 2005-05-09 | 2006-12-13 | 贵阳云岩西创药物科技开发有限公司 | 丹灯脑通药物制剂及其制备方法和质量控制方法 |
Non-Patent Citations (3)
Title |
---|
何洋: "丹灯通脑胶囊质量控制方法与有效成分葛根素药动学研究", 《中国优秀硕士学位论文全文数据库医药卫生科技辑》 * |
国家药典委员会: "《中华人民共和国药典2010年版一部》", 31 January 2010 * |
张雪慧: "复方斑蝥片含量测定研究", 《现代中医药》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106596777A (zh) * | 2016-12-20 | 2017-04-26 | 神威药业集团有限公司 | 丹灯通脑制剂的质量控制方法 |
CN106596777B (zh) * | 2016-12-20 | 2019-05-24 | 神威药业集团有限公司 | 丹灯通脑制剂的质量控制方法 |
CN115957289A (zh) * | 2022-11-25 | 2023-04-14 | 国药集团同济堂(贵州)制药有限公司 | 一种柴葛畅原合剂制剂及其制备方法和检测方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102841153B (zh) | 2014-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101766771A (zh) | 一种治疗妇科疾病药物的质量控制方法 | |
CN109212083A (zh) | 复方鸡内金咀嚼片的质量检测方法 | |
CN103808835B (zh) | Hplc-dad法同时测定四物汤煎剂中10种化学成分含量的方法 | |
CN112903867A (zh) | 一种苓桂术甘汤物质基准的质量控制方法 | |
CN101966223A (zh) | 一种复方扶芳藤制剂的指纹图谱检测方法 | |
CN110940749B (zh) | 一种同时检测治疗儿童咳嗽的中药四种成分含量的方法 | |
CN110045050B (zh) | 一种乙肝解毒胶囊中七种原料药的鉴别检测方法 | |
CN109633003A (zh) | 一种测定远志中远志口山酮ⅲ和3,6,-二芥子酰基蔗糖含量的方法 | |
CN104007198B (zh) | 一种灵芝皇制剂hplc标准指纹图谱及其构建方法和应用 | |
CN104597139A (zh) | Hplc同时测定裸花紫珠制剂中三种苯乙醇苷类成分的方法 | |
CN102841153B (zh) | 一种丹灯通脑药物制剂的质量控制方法 | |
CN102706984A (zh) | 采用高效液相测定清肺消炎丸中盐酸麻黄碱含量的方法 | |
CN100372563C (zh) | 治疗支气管炎的复方制剂及其制备方法、质量控制方法 | |
CN102008541B (zh) | 无糖型复方扶芳藤制剂中3种主要活性成分的同时检测方法 | |
CN101700306A (zh) | 一种乳癖消制剂的质量控制方法 | |
CN107764924B (zh) | 哮喘颗粒中有效成分的检测方法 | |
CN112924583B (zh) | 佩兰中吡咯里西啶生物碱的测定方法 | |
CN101953913B (zh) | 中风回春胶囊的质量分析方法 | |
CN105486761A (zh) | 一种中药颗粒剂中黄芩苷的含量测定方法 | |
CN103575823A (zh) | 一种糖敏灵制剂中8种化学成分的检测方法 | |
CN102768248A (zh) | 测定骨松宝制剂中朝藿定c及淫羊藿苷含量的方法 | |
CN112666278A (zh) | 华佗再造丸中士的宁的限量检测方法 | |
CN102526128B (zh) | 一种中药灵芝颗粒及其制备方法和检测方法 | |
CN113960186B (zh) | 清肺排毒颗粒中枳实有效成分的定量方法 | |
CN111337599A (zh) | 一种预处理方法、吗啡的检测方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20121226 Assignee: YUNNAN SHENWEI SHIPURUI PHARMACEUTICAL Co.,Ltd. Assignor: Yunnan Spirin Biological Engineering Co.,Ltd. Contract record no.: 2016530000006 Denomination of invention: Quality control method of dandeng brain dredging pharmaceutic preparation Granted publication date: 20141105 License type: Exclusive License Record date: 20160126 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141105 |
|
CF01 | Termination of patent right due to non-payment of annual fee |